The Mitsubishi Tanabe Pharma Group may engage with Patient Organisations (POs) across Europe. In accordance with the EFPIA Code. Disclosure of Transfers of Value from Pharmaceutical Companies 2019, details of Transfers of Value made to POs in Europe by the Mitsubishi Tanabe Pharma Group can be found below.
The methodology applied in preparing and collating these figures is available here in English*
If you are a Healthcare Professional and have any questions regarding the figures disclosed, please contact:
2021 Transfers of Value
|Interactions with PO’s in 2021|
|PO Name||Funding||Country||Description of Interaction|
| SCLERODERMA & RAYNAUD’S UK|
|GBP 5,000.00||United Kingdom|| Event Sponsorship – GBP 5,000.00 (plus VAT)|
Mitsubishi Tanabe Pharma Development America (MTDA)
SRUK Virtual Conference 2021
This virtual event was hosted by leading clinicians and researchers, covering areas of research funded by SRUK, advice on symptom management, and discussions about the future, including health and wellbeing workshops.
The sponsorship funds were used exclusively to support and fund expenses directly related to the above named event. MTDA had no control, authority or ability to influence any decisions regarding how this funding was used, for which the event organisers are solely responsible.
* The Mitsubishi Tanabe Pharma Group has established legal entities in the United Kingdom, Germany and Switzerland and therefore disclosure is made according to local requirements for these countries
Terms and Privacy
Mitsubishi TANABE Pharma Europe Ltd
69 Old Broad Street